Articles

Podcasts

Videos

Cardiology

The LIVMOR Halo AF Detection System has received 510(k) clearance from the US FDA and becomes the first prescriptible wearable for continuous heart monitoring in patients with atrial fibrillation.

FDA Approves Wearable for Heart Monitoring

The investigators also found the effects of dapagliflozin were similar in patients with type 2 diabetes and those without type 2 diabetes.

Study Shows Dapagliflozin Effective Against Chronic Kidney Disease

Cytokinetics announces presentations on two trials assessing omecamtiv mecarbil in patients with heart failure and reduced ejection fraction. 

New Data Offers Insight into HFrEF Patient Risk, Treatment Potential

This edition from the 10 Year Plan features perspective from leadership at ACC and ESC, as well as survey results from cardiologists.

Cardiologists Seek Equity in the Improvement of their Field

Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction. 

SGLT2 Inhibitors Emerge As Treatment Options for Heart Failure Patients

Approximately 11.7% of nearly 90,000 hospitalized patients with confirmed influenza suffered from an acute cardiovascular event.

Investigators Discover Link Between Influenza Epidemics and Acute Cardiovascular Events

In a cross-sectional study among CAD patients, investigators found that 30.3% of heart team treatment recommendations diverged from original consultation. 

Heart Team Recommendations Conflict with Original CAD Treatment

What does personalized outpatient care look like for a cardiology institute during the pandemic?

Concierge Medicine and Cardiac Care During COVID-19

The technologies help patients with heart rhythm disorders monitor their healthcare and stay connected with their physicians.

FDA Approves Implantable Heart Rhythm Monitoring Devices

A systematic review and network meta-analysis is comparing 9 classes of therapies for HbA1c and risk management in patients with low versus increased cardiovascular risk.